Chengdu Olymvax Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Chengdu Olymvax Biopharmaceuticals has a total shareholder equity of CN¥921.0M and total debt of CN¥377.4M, which brings its debt-to-equity ratio to 41%. Its total assets and total liabilities are CN¥1.7B and CN¥786.6M respectively.
Key information
41.0%
Debt to equity ratio
CN¥377.37m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥269.46m |
| Equity | CN¥920.95m |
| Total liabilities | CN¥786.63m |
| Total assets | CN¥1.71b |
Recent financial health updates
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Recent updates
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected
Oct 09We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Financial Position Analysis
Short Term Liabilities: 688319's short term assets (CN¥899.7M) exceed its short term liabilities (CN¥483.8M).
Long Term Liabilities: 688319's short term assets (CN¥899.7M) exceed its long term liabilities (CN¥302.8M).
Debt to Equity History and Analysis
Debt Level: 688319's net debt to equity ratio (11.7%) is considered satisfactory.
Reducing Debt: 688319's debt to equity ratio has increased from 4.1% to 41% over the past 5 years.
Debt Coverage: 688319's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 688319's interest payments on its debt are well covered by EBIT.